Rick Doblin and MAPS: The Man Who Never Gave Up on Psychedelic Therapy (2026 Update)

Rick Doblin and MAPS: The Man Who Never Gave Up on Psychedelic Therapy (2026 Update)

How one determined scientist spent nearly 40 years building the path to legal psychedelic medicine — and what the FDA setback of 2024 means for the future.

Who Is Rick Doblin?

Rick Doblin is the founder and president of MAPS — the Multidisciplinary Association for Psychedelic Studies. He is, arguably, the single most influential person in the modern psychedelic therapy movement. While researchers, therapists, and advocates have all contributed to the growing interest in psychedelic medicine, Rick Doblin MAPS work over nearly four decades has done more than almost anyone else to push the science from the margins into the mainstream.

He is not a headline-chasing celebrity or a counterculture icon. He is a meticulous, persistent scientist who has spent his life navigating drug regulation, clinical research, and public health. His story is one of extraordinary patience.

Early Life: A Transformative Experience

Rick Doblin was born in 1953. As a young man studying at New College of Florida, he encountered writings about psychedelics and their potential therapeutic applications. This reading led him to a personal LSD experience that he describes as profoundly meaningful — one that reshaped his understanding of the human mind and its capacity for healing.

Rather than simply moving on, Doblin made a decision that would define his life. He wanted to understand the science behind what he had experienced. Moreover, he wanted to make these experiences legally and safely available to others who might benefit from them. This was not an easy ambition. In the early 1980s, psychedelic research was essentially banned, stigmatized, and politically toxic.

Doblin went on to complete a doctorate in public policy at Harvard's Kennedy School of Government in 2001 — a degree he pursued specifically to understand how to navigate the regulatory and political systems that stood between psychedelic compounds and legitimate medicine.

Founding MAPS in 1986

In 1986, Rick Doblin founded MAPS — the Multidisciplinary Association for Psychedelic Studies. The timing was significant. That same year, the U.S. Drug Enforcement Administration (DEA) moved to classify MDMA as a Schedule I substance, despite a recommendation from a federal administrative law judge that it be placed in the less restrictive Schedule III. The door to legal research was being slammed shut.

Doblin founded Rick Doblin MAPS with a clear long-term goal: to develop psychedelic and marijuana therapies and eventually bring them through the FDA approval process. This was considered unrealistic by most people at the time. MDMA was being associated with raves and recreational drug use in the press. Psilocybin mushrooms were still firmly in the counterculture. The political climate was defined by the "War on Drugs."

None of that stopped him. For the next two decades, MAPS quietly funded research, built scientific credibility, and developed relationships with regulatory agencies. The organization is funded entirely by private donations — no government funding, no pharmaceutical money — which gave it a level of independence that proved crucial.

To understand how the broader psychedelic renaissance connects to traditional and cultural roots, it is worth reading our introduction to shamanism and magic mushrooms, which explores how plant medicines have been used for healing across cultures for thousands of years.

The MDMA-Assisted Therapy Campaign

The flagship project of Rick Doblin MAPS became the clinical development of MDMA-assisted therapy for post-traumatic stress disorder (PTSD). PTSD is a severe, often treatment-resistant condition that affects millions of people worldwide — veterans, survivors of sexual violence, accident survivors, and others who have experienced trauma.

MAPS began Phase 2 clinical trials for MDMA-assisted PTSD therapy in the early 2000s. The results were promising enough that, in 2017, the FDA granted the program Breakthrough Therapy Designation — a recognition that early evidence suggested the treatment offered substantial improvement over existing options. This was a major milestone.

Two Phase 3 trials followed, representing the gold standard of clinical evidence. The results showed significant reductions in PTSD symptoms for participants receiving MDMA-assisted therapy compared to placebo. In some studies, over two-thirds of participants no longer met diagnostic criteria for PTSD after treatment.

To handle the regulatory submission and eventual commercialization, MAPS created a public benefit corporation in 2014 — originally called MAPS PBC — which was later renamed Lykos Therapeutics in January 2024 after raising over $100 million in investment. The New Drug Application (NDA) was submitted to the FDA, and approval seemed within reach.

If you want to understand more about why psilocybin and other psychedelics have such powerful effects on the mind, our article on mushrooms and the mind is a good place to start.

The FDA Setback: August 2024

In August 2024, the FDA issued a Complete Response Letter (CRL) to Lykos Therapeutics — effectively declining to approve MDMA-assisted therapy for PTSD and requesting additional evidence before the application could move forward. It was a significant blow, though not a final rejection.

The FDA raised concerns about the therapeutic model used in the trials, adverse event reporting, the durability of treatment effects, and the difficulty of maintaining a proper double-blind design when participants can feel the effects of MDMA. The agency also asked for consideration of a low-dose comparison arm in future studies — a design element that, according to Doblin, the FDA itself had previously recommended against during the Special Protocol Assessment negotiations.

Doblin's public response to the FDA Complete Response Letter was measured but firm. He described the setback as "not yet, not no" — a phrase that captures both the disappointment and the determination. In a September 2025 press briefing, after the FDA publicly released the full CRL text for the first time, he stated that the FDA had "moved the goalposts," raising study design concerns that had not been flagged during the original protocol agreement.

Following the CRL, Lykos Therapeutics laid off around 75% of its workforce. Doblin stepped down from the Lykos board but remained at the helm of MAPS itself. By August 2025, Lykos had rebranded again as Resilient Pharmaceuticals — a name that signals intent to continue rather than retreat. Negotiations with the FDA were ongoing, and Doblin has said he believes eventual approval is likely, though it may take several more years.

The Psychiatric Times interview with Rick Doblin on the FDA CRL offers a detailed and nuanced look at how he interprets the setback and what he believes the path forward requires.

Beyond MDMA: MAPS in 2026

Rick Doblin MAPS work has never been limited to MDMA. In 2026, MAPS continues to pursue a broad agenda across research, policy, and education.

On the psilocybin front, MAPS has been actively engaged in policy advocacy and international research collaboration. Australia became the first country to authorize the therapeutic use of psilocybin for treatment-resistant depression and MDMA for PTSD in 2023 — a milestone that MAPS supported and celebrated. Colorado and Oregon have moved forward with legal psilocybin treatment frameworks in the United States, and Rick Doblin MAPS has contributed to the policy discussions shaping how those frameworks operate.

MAPS also runs the Zendo Project, a psychedelic harm reduction program that provides trained support for people having difficult experiences at festivals and other events. This work reflects a core MAPS philosophy: that safer access and better support structures reduce harm and build the case for responsible therapeutic use. Our own article on navigating difficult psychedelic experiences explores similar harm reduction principles.

In December 2025, Doblin announced that MAPS had entered a new chapter under co-executive directors Betty Aldworth and Ismail "Izzy" Lourido Ali. Doblin described this transition as part of a multigenerational approach — building an organization that will outlast any single leader. His own role has shifted toward long-term vision and global advocacy, including therapist training programs in Ukraine, Poland, and other high-trauma regions.

The VA announced funding for an MDMA-PTSD study in early 2026, described as the first VA-funded psychedelic therapy study since the 1960s. This represents a meaningful shift in the institutional landscape — the very federal agencies that once closed the door to this research are now funding it.

If you're curious about the therapeutic potential of psilocybin specifically, our article on the healing power of psilocybin provides a solid foundation. And for context on the wider psychedelic renaissance, our profile of Albert Hofmann — the chemist who first synthesized LSD — shows just how long this story has been in the making.

His Vision: Therapy, Not Recreation

It is worth being clear about what Rick Doblin MAPS is actually working toward. His goal is not recreational legalization. He envisions a regulated system of licensed clinics where trained therapists can administer psychedelic compounds under carefully controlled conditions to people with specific mental health conditions. In fact, his framework specifically argues that psychedelic therapy is most beneficial — and most defensible — when embedded in proper therapeutic support, preparation, and integration.

This distinction matters. MAPS is not advocating for open access to MDMA or psilocybin at pharmacies. The organization is arguing for a medical model: rigorous screening, trained guides, structured sessions, and follow-up integration. This is why the FDA's concerns about the therapeutic model used in trials cut so deeply — that model is the heart of what MAPS has built.

For those interested in how set, setting, and intention shape psychedelic experiences, our article on how to turn your experience into a ceremony explores some of the same principles that underpin the therapeutic approach.

The Legacy of Rick Doblin MAPS (2026)

After nearly 40 years, the question is not whether Rick Doblin MAPS has been consequential. The answer to that is clearly yes. The question is whether the work he started will reach its original destination.

MAPS raised over $140 million in philanthropic donations and facilitated the first two successful Phase 3 trials of a psychedelic-assisted therapy in history. The organization trained hundreds of therapists. It built credibility with regulatory agencies, shifted the political conversation, and created a global network of researchers, advocates, and practitioners who continue to push the field forward.

The FDA setback of 2024 was real, and it hurt. However, the broader institutional environment has shifted considerably since Doblin founded MAPS in a world where this work seemed almost impossible. Veterans' affairs departments are funding research. Major universities have psychedelic research centers. Australia has regulatory approval in place. The momentum is real, even if the timeline has been extended.

Doblin himself remains optimistic. In a December 2025 message from MAPS, he wrote about entering "the next generation of MAPS' new mission" — globalizing access, training therapists in underserved regions, and continuing to build the infrastructure for a future where legal, supported psychedelic therapy is available to those who need it most.

To read more about other figures who helped lay the groundwork for this moment, explore our profiles of Terence McKenna and Timothy Leary and Ram Dass — thinkers whose work, whatever its contradictions, helped keep these conversations alive during the decades when official science had gone silent.

And if you're new to the subject of psychedelics more broadly, our introductory guide to what magic mushrooms are is a clear, accessible starting point.